logo-loader
RNS
Oxford BioDynamics PLC

Oxford BioDynamics - PDMR Dealing

RNS Number : 2384D
Oxford BioDynamics PLC
02 April 2025
 

                                                                      

A picture containing icon Description automatically generated

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

PDMR Dealing

2 April 2025 - Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that on 1 April 2025, the Company's Chief Financial Officer Paul Stockdale transferred 791,176 ordinary shares of 0.1 pence each ("Ordinary Shares") into his ISA. The transfer was effected through a sale of 791,176 Ordinary Shares at 0.45p and the repurchase of 791,176 Ordinary Shares at 0.454p.

 

Following these transactions, Paul Stockdale remains beneficially interested in a total of 3,077,919 Ordinary Shares, representing approximately 0.16% of the Company's current issued share capital.

The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further details:

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Paul Stockdale

2

Reason for the notification

a)

Position/status 

Director/PDMR

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc 

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 0.1 pence each

 

 

ISIN:   GB00BD5H8572

b)

Nature of the transaction

Transfer of shares into ISA through sale and re-purchase of 791,176 Ordinary Shares  

c)

Price(s) and volume(s)

 


Price(s)

Volume(s)

Sale

£0.00450

791,176

Purchase

£0.00454

791,176

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

n/a

 

e)

Dates of the transactions

1 April 2025

f)

Place of the transaction

London Stock Exchange (XLON)

 

-Ends-

For further details please contact:

Oxford BioDynamics Plc

Iain Ross, Executive Chairman

Paul Stockdale, CFO

 

+44 (0)1865 518910

Shore Capital - Nominated Adviser and Broker

Advisory: Stephane Auton / Lucy Bowden

Broking: Fiona Conroy

 

+44 (0)20 7408 4090

WG Partners - Joint Broker

David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby

 

+44 (0)20 3705 9330

OAK Securities - Joint Broker

Jerry Keen / Henry Clarke / Damion Carruel

 

 

+44 (0)20 3973 3678

Camarco - Financial PR

Marc Cohen / Tilly Butcher / Fergus Young

 

 

+44 (0)20 3757 4980

OBDFinancial@camarco.co.uk

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com,  X (@OxBioDynamics) or LinkedIn.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHIBMRTMTAMBJA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Oxford BioDynamics' Bartu Ahiska on breakthrough CFS test

Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) senior director of commercial development & marketing comms, Bartu Ahiska, talked with Proactive's Stephen Gunnion about the company’s breakthrough diagnostic blood test for chronic fatigue syndrome (CFS), also known as ME. Ahiska said this was...

on 10/13/2025

4 min read